The study objective was to evaluate the effect of atrasentan compared with placebo on time to
doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in
participants with type 2 diabetes and nephropathy who were treated with the maximum tolerated
labeled daily dose (MTLDD) of a renin-angiotensin system (RAS) inhibitor. In addition, the
study assessed the effects of atrasentan compared with placebo on cardiovascular (CV)
morbidity and mortality, urine albumin excretion, changes in estimated glomerular filtration
rate (eGFR), as well as the impact on quality of life in participants with type 2 diabetes
and nephropathy.